Piper Sandler Rates Glaukos (GKOS) buy, $165 Price Target

Piper Sandler maintains a buy rating on Glaukos with a $165 price target, a 18.06% upside from the current price.

By EarningsIQ Research Desk · Published Jul 1, 2026, 10:00 AM EDT · Updated Jul 1, 2026, 3:01 PM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Piper Sandler rated Glaukos Corporation ($GKOS) "buy" with a $165 price target on July 1, 2026.

Since the rating, $GKOS is up 11.2% after 1 week, up 21.2% after 1 month and up 19.8% to date (from the $137.57 close on Jul 1, 2026).

GKOS Glaukos Corporation

$164.84 +48.88% year to date

Daily close · Oct 16, 2026

Key Points

Piper Sandler reiterated its buy rating on Glaukos Corporation (GKOS) with a $165 price target on July 1, 2026.
Piper Sandler's $165 price target implies 18.06% upside from Glaukos Corporation's ($GKOS) current $139.76 share price.
Shares of NYSE:GKOS traded near $139.76 on Wednesday, with a market cap of $8.21 billion and a forward P/E of 315.0.
Recent insider sales included 4,059 shares by CEO Thomas Burns on June 25, 2026, at $142.57 per share.

Get $GKOS trade alerts by text

We text you when insiders, Congress or big funds trade $GKOS. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Glaukos Corporation alert may contain errors. Disclosures

Piper Sandler has reiterated its buy rating on Glaukos Corporation (NYSE:GKOS), maintaining a price target of $165. The analyst, Adam Maeder, issued the update on July 1, 2026. On that day, shares of Glaukos traded near $139.76.

Analyst rating track record

Piper Sandler vs. the S&P 500

YTD return -8.95% hypothetical

All-time return +36.18% S&P 500 +36.53%

vs. S&P 500 -0.35% behind the index

Hypothetical returns from Piper Sandler's disclosed trades, not real profit or advice. How we model this.

Glaukos Corporation Stock Down 14.7%

Shares of Glaukos Corporation, trading on the NYSE under the ticker GKOS, were near $139.76 on Wednesday. The company has a market cap of approximately $8.21 billion and a forward P/E ratio of 315.0, which suggests high growth expectations. Its beta is 0.815, indicating less volatility compared to the market. The stock's 52-week range has been between $73.16 and $148.11, with a 50-day moving average of $128.20 and a 200-day moving average of $109.22. Glaukos maintains a strong financial position with a current ratio of 5.43 and a quick ratio of 4.43, alongside a low debt-to-equity ratio of 15.78.

12-month forecast

$GKOS price target

Glaukos Corporation daily closes and this analyst's $165 target. Not advice.

Recent Earnings

In its most recent earnings report, Glaukos Corporation reported revenue of approximately $551.35 million, reflecting a growth rate of 41.2%. However, the company is not yet profitable, with a net margin of -34.3% and a return on equity (ROE) of -26.4%. The next earnings release is expected on April 29, 2026.

Insider Buying and Selling at Glaukos Corporation

There was notable insider activity at Glaukos Corporation recently. On June 25, 2026, CEO Thomas Burns sold 4,059 shares at an average price of $142.57. Additionally, President and COO Joseph Gilliam sold 1,056 shares on the same day at the same price. Chief Development Officer Tomas Navratil also sold 483 shares. These transactions were not part of a pre-arranged 10b5-1 trading plan.

Analysts Set New Price Targets

On July 1, 2026, Piper Sandler reiterated its buy rating for Glaukos Corporation with a price target of $165. Other analysts have also shown support: Needham maintained a buy rating with a $150 target on June 17, 2026, and Citigroup maintained a buy rating with a $162 target on June 11, 2026. Overall, Glaukos has a consensus rating of "strong buy" with an average target price of $157.50 from 12 analysts.

About Glaukos Corporation

Glaukos Corporation is a healthcare company based in Aliso Viejo, California. It specializes in developing medical devices and pharmaceuticals for eye disorders, including glaucoma and retinal diseases. The company's flagship products include the iStent and iStent inject W, micro-bypass stents for treating glaucoma, and the iDose TR, a drug delivery system for intraocular pressure reduction. Glaukos is led by CEO Thomas William Burns and employs around 1,094 people.

Bottom Line

Piper Sandler's reiterated buy rating and $165 target for Glaukos Corporation reflect continued confidence in the company's growth potential. Investors track such analyst updates closely, though it's important to remember that these ratings are based on past performance and future expectations. The company's strong financial ratios and innovative product line make it a key player in the medical devices industry.